Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds PALO ALTO, Calif. May 9, 2024 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights • Revenue of $168.5 million for the first quarter of 2024, an increase of 31% over the first quarte ...